Evaluating Oncolytics Biotech’s Pipeline with VC Method

zsinkala , , , ,

Evaluation of Oncolytics Biotech’s Pipeline Using the Venture Capital Method

Evaluating the pipeline of Oncolytics Biotech using the Venture Capital (VC) method involves several steps. The VC method is often used to estimate the potential value of early-stage companies based on projected future cash flows, the probability of success, and exit strategies. Here’s a step-by-step guide:

Step 1: Identify Key Projects in the Pipeline

For this evaluation, we will focus on the key clinical trials for pelareorep:

  1. Breast Cancer (HR+/HER2- Metastatic Breast Cancer)
  2. Colorectal Cancer
  3. Hematological Cancers (Multiple Myeloma)

Step 2: Estimate Potential Market Size

For each indication, estimate the potential market size and the share Oncolytics could capture:

a. Breast Cancer

  • Estimated number of new cases in the U.S. annually: 276,480
  • Estimated treatment cost per patient per year: $100,000
  • Market Size: $27.648 billion (calculated as 276,480 × 100,000)

b. Colorectal Cancer

  • Estimated new cases annually: 106,180
  • Estimated treatment cost per patient per year: $75,000
  • Market Size: $7.964 billion (calculated as 106,180 × 75,000)

c. Hematological Cancers

  • Estimated new cases annually (combined): 82,090 (61,450 for Multiple Myeloma + 20,640 for Hodgkin lymphoma)
  • Estimated treatment cost per patient per year: $150,000
  • Market Size: $12.3135 billion (calculated as 82,090 × 150,000)

Step 3: Estimate Probability of Success for Each Project

For early-stage biotechs, the probability of success typically ranges from 10% to 30% depending on the phase of development:

  • Breast Cancer: 30% (Phase 2)
  • Colorectal Cancer: 20% (Phase 1/2)
  • Hematological Cancers: 25% (Phase 1)

Step 4: Calculate Expected Revenue for Each Project

Using the estimated market sizes and the probability of success:

a. Breast Cancer

Expected Revenue: $8.2944 billion (calculated as 27.648 billion × 0.30)

b. Colorectal Cancer

Expected Revenue: $1.5928 billion (calculated as 7.964 billion × 0.20)

c. Hematological Cancers

Expected Revenue: $3.078375 billion (calculated as 12.3135 billion × 0.25)

Step 5: Total Expected Revenue

Sum the expected revenues from all projects:

Total Expected Revenue: 8.2944 + 1.5928 + 3.078375 = 12.965575 billion

Step 6: Determine the Exit Multiple

Venture capitalists often use exit multiples based on revenue when estimating the potential value of a biotech company. A typical exit multiple for a biotech company in the late stages could be between 4x and 10x of projected revenues:

Assume a conservative exit multiple of 5x.

Step 7: Estimate the Potential Valuation

Using the exit multiple and the total expected revenue:

Potential Valuation: 12.965575 billion × 5 = 64.827875 billion

Step 8: Consider Investment Risks and Adjustments

  • Dilution: Account for potential dilution in future financing rounds.
  • Regulatory Risks: Consider the impact of potential regulatory setbacks.
  • Market Competition: Factor in competition from other therapies or companies.

Conclusion

Using the VC method and basic math, the evaluation of Oncolytics Biotech’s pipeline suggests a potential valuation of approximately $64.83 billion under favorable conditions. However, this valuation must be adjusted for the risks associated with clinical development, market competition, and funding requirements.

This structured approach allows investors to gauge the potential of Oncolytics Biotech’s pipeline and make informed investment decisions based on projected market sizes, probabilities of success, and potential exit strategies.